Cellectis (CLLS) Cash from Operations Growth (5y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.75% |
| Dec 31, 2025 | 21.10% |
| Sep 30, 2025 | 42.78% |
| Jun 30, 2025 | 14.24% |
| Mar 31, 2025 | -68.96% |
| Dec 31, 2024 | 63.56% |
| Sep 30, 2024 | 23.77% |
| Jun 30, 2024 | 34.85% |
| Mar 31, 2024 | -0.81% |
| Dec 31, 2023 | 32.63% |
| Sep 30, 2023 | -2.63% |
| Jun 30, 2023 | -8.71% |
| Mar 31, 2023 | -7.23% |
| Dec 31, 2022 | 33.69% |
| Sep 30, 2022 | -10.95% |
| Jun 30, 2022 | -6.26% |
| Mar 31, 2022 | -17.60% |
| Dec 31, 2021 | -71.11% |
| Sep 30, 2021 | -74.02% |
| Jun 30, 2021 | -2.45% |
| Mar 31, 2021 | -13.63% |
| Dec 31, 2020 | -26.39% |
| Sep 30, 2020 | -38.02% |
| Jun 30, 2020 | -4.46% |
| Mar 31, 2020 | 25.06% |